The effect of thalidomide on arachidonic acid metabolism in human polymorphonuclear leukocytes and platelets

Maurice, P; Barkley, A. S. J.; Allen, B.R.

doi:10.1111/j.1365-2133.1986.tb06648.x

Cited by 7 publications

(2 citation statements)

References 15 publications

(7 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Another possible mechanism is that TNF-mediated down regulation of Na + /K + -ATPase abolished sodium absorption, as the process is dependent on the function of Na + /K + -ATPase in the basolateral membrane that caused diarrhea [202]. Other mechanisms, such as inhibition of COXs [203,204], PGs [205] and cytokines such as interleukins (ILs) [206], are also implicated. Thalidomide may also inhibit TNF-α-driven calcium and potassium…”

Section: Oral Alkalinizing Agentsmentioning

confidence: 99%

Novel Agents that Potentially Inhibit Irinotecan-Induced Diarrhea

Yang¹,

Chan³

et al. 2005

CMC

View full text Add to dashboard Cite

Irinotecan (CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin) has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting DNA topoisomerase I (Topo I). However, severe and unpredictable dosing-limiting toxicities (mainly myelosuppression and severe diarrhea) hinder its clinical use. The latter consists of early and late-onset diarrhea, occurring within 24 hr or > or = 24 hr after CPT-11 administration, respectively. This review highlights novel agents potentially inhibiting CPT-11-induced diarrhea, which are designed and tested under guidance of disposition pathways and potential toxicity mechanisms. Early-onset diarrhea is observed immediately after CPT-11 infusion and probably due to the inhibition of acetylcholinesterase activity, which can be eliminated by administration of atropine. Late-onset diarrhea appears to be associated with intestinal exposure to SN-38 (7-ethyl-10-hydroxycamptothecin), the major active metabolite of CPT-11, which may bind to Topo I and induce apoptosis of intestinal epithelia, leading to the disturbance in the absorptive and secretory functions of mucosa. CPT-11 and SN-38 may also stimulate the production of pro-inflammatory cytokines and prostaglandins (PGs), thus inducing the secretion of Na(+) and Cl(-). Early treatment of severe late-onset diarrhea with oral high-dose loperamide has decreased patient morbidity. Extensive studies have been conducted to identify other potential agents to ameliorate diarrhea in preclinical and clinical models. These include intestinal alkalizing agents, oral antibiotics, enzyme inducers, P-glycoprotein (PgP) inhibitors, cyclooxygenase-2 (COX-2) inhibitors, tumor necrosis factor-alpha (TNF-alpha) inhibitors, or blockers of biliary excretion of SN-38. Further studies are needed to identify the molecular targets associated with CPT-11 toxicity and safe and effective agents for alleviating CPT-11-induced diarrhea.

show abstract

Section: Oral Alkalinizing Agentsmentioning

confidence: 99%

Novel Agents that Potentially Inhibit Irinotecan-Induced Diarrhea

Yang¹,

Chan³

et al. 2005

CMC

View full text Add to dashboard Cite

show abstract

“…Ramselaar tras tratar a un paciente afecto de síndrome de neuro-Beh,et con una asociación de talidomida-clorambucil-prednisona, obtuvo la curación del mismo sin recaídas durante el período de obseivación posterior 2 animado por los buenos resultados obtenidos en el tratamiento de la leprorreacción, utilizó la talidomida en 20 pacientes afectos de lupus eritematoso discoide con una dosis inicial de 300 mg, para llegar a una dosis de mantenimiento de 25 mg, pauta con la ~ue logró mejoría clínica e histológica en todos los casos ' . Hasper trató con talidomida 11 pacientes afectos de lupus eritematoso crónico resistentes a la cloroquina, consiwiendo, en la mayoría de ellos, remisión clínica completa 4 • Dos pacientes que presentaban lupus eritematoso subagudo fueron tratados con talidomida a dosis bajas. En ambos se obtuvo una rápida mejoría de las lesiones cutáneas y en uno de ellos.…”

unclassified

Talidomida. Nuevas utilidades en dermatología

Delás

Leache

et al. 2017

revista-de-medicina

View full text Add to dashboard Cite

Se comentan las indicaciones y toxicidad de la talidomida. Tras revisar la bibliografía existente y a la luz de la experiencia de los autores, se considera a la talidomida un fármaco de primera línea en el tratamiento de la aftosis mucocutánea crónica recidivante. Sus efectos teratogénicos limitan la utilización del fármaco en mujeres en edad fértil. En varones es la neurotoxicidad el efecto secundario más importante. Ocasionalmente será un fármaco útil en otras enfermedades como el lupus eritematoso discoide crónico y subagudo, prúrigo nodular y pioderma gangrenoso, entre otras. Son necesarios controles neurológicos y neurofisiológicos periódicos

show abstract

Peculiarities and Possible Mode of Actions of Thalidomide

Neubert¹,

Neubert²

1997

Drug Toxicity in Embryonic Development II

View full text Add to dashboard Cite

The effect of thalidomide on arachidonic acid metabolism in human polymorphonuclear leukocytes and platelets

Cited by 7 publications

References 15 publications

Novel Agents that Potentially Inhibit Irinotecan-Induced Diarrhea

Novel Agents that Potentially Inhibit Irinotecan-Induced Diarrhea

Talidomida. Nuevas utilidades en dermatología

Peculiarities and Possible Mode of Actions of Thalidomide

Contact Info

Product

Resources

About